Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 2Recurrence 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

venetoclax 3Cytarabine 3zosuquidar trihydrochloride 2Immunotherapy, Adoptive 2ponatinib 1gilteritinib 1fludarabine phosphate 1fludarabine 1enasidenib 1blinatumomab 1asciminib 1Sensitivity and Specificity 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Idarubicin 1Gemtuzumab 1Filgrastim 1Daunorubicin 14-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 12-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myeloid × Gemtuzumab × Clear all
NCT00233909 2008-04-01

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Kanisa Pharmaceuticals

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡